Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will compare the clinical efficacy of inhaled iloprost as an invasive, selective
vasodilator in the cardiac catheterization laboratory in patients with pulmonary hypertension
to the gold standard of inhaled nitric oxide. It will also examine whether echocardiographic
estimates of response to inhaled iloprost can predict responsiveness to invasive vasodilator
testing in patients with pulmonary hypertension.